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 Introduction 
 Inhaled anti-infl ammatory agents and bronchodilators such as corticoste-
roids, muscarinic antagonists and β 2 -agonists are central to the pharma-
cological management of chronic obstructive pulmonary disease (COPD) 
( 1 , 2 ). Combinations of drugs with distinct and complementary mecha-
nisms of action may off er improved effi  cacy in the treatment of COPD ( 2 ), 
which may in turn help to relieve the burden of COPD on daily activities. 
Furthermore, clinical studies have shown the use of an inhaled corticoste-
roid/long-acting β 2 -agonist (ICS/LABA) combination together with a long-
acting muscarinic antagonist (LAMA) is well tolerated in patients with 
COPD and associated with improvements in lung function, symptoms, 
 Abstract 
 Combinations of drugs with distinct and complementary mechanisms of action may 
offer improved effi cacy in the treatment of chronic obstructive pulmonary disease 
(COPD). In two 12-week, double-blind, parallel-group studies, patients with COPD 
were randomized 1:1:1 to once-daily umeclidinium (UMEC; 62.5 μg and 125 μg) 
or placebo (PBO), added to twice-daily fl uticasone propionate/salmeterol (FP/
SAL; 250/50 μg). In both studies, the primary effi cacy measure was trough forced 
expiratory volume in 1 second (FEV 1 ) at Day 85. Secondary endpoints were weighted-
mean (WM) FEV 1 over 0–6 hours post-dose (Day 84) and rescue albuterol use. Health-
related quality of life outcomes (St. George's Respiratory Questionnaire [SGRQ] and 
COPD assessment test [CAT]) were also examined. Safety was assessed throughout. 
Both UMEC+FP/SAL doses provided statistically signifi cant improvements in trough 
FEV 1 (Day 85: 0.127–0.148 L) versus PBO+FP/SAL. Similarly, both UMEC+FP/SAL 
doses provided statistically-signifi cant improvements in 0–6 hours post-dose WM 
FEV 1  versus PBO+FP/SAL (Day 84: 0.144–0.165 L). Rescue use over Weeks 1–12 
decreased with UMEC+FP/SAL in both studies  versus PBO+FP/SAL (Study 1, 0.3 
puffs/day [both doses]; Study 2, 0.5 puffs/day [UMEC 125+FP/SAL]). Decreases 
from baseline in CAT score were generally larger for both doses of UMEC+FP/SAL 
versus PBO+FP/SAL (except for Day 84 Study 2). In Study 1, no differences in SGRQ 
score were observed between UMEC+FP/SAL and PBO+FP/SAL; however, in Study 2, 
statistically signifi cant improvements were observed with UMEC 62.5+FP/SAL (Day 
28) and UMEC 125+FP/SAL (Days 28 and 84) versus PBO+FP/SAL. The incidence of 
on-treatment adverse events across all treatment groups was 37–41% in Study 1 and 
36–38% in Study 2. Overall, these data indicate that the combination of UMEC+FP/
SAL can provide additional benefi ts over FP/SAL alone in patients with COPD. 
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and health status compared with individual ICS/LABA 
or LAMA therapy ( 3 – 5 ). Th ese fi ndings are refl ected 
in the current version of Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) guidelines, which 
recommend the combined use of an ICS/LABA prod-
uct with a LAMA as a secondary treatment option for 
symptomatic patients with severe airfl ow obstruction 
and at high risk of exacerbations ( 2 ). 
 Fluticasone propionate plus salmeterol (FP/SAL; 
GSK, London, UK) is an ICS/LABA combination indi-
cated for maintenance treatment of airfl ow obstruc-
tion and for reduction of exacerbations in patients 
with COPD ( 6 ). Th e LAMA umeclidinium (UMEC, 
GSK573719; GSK, London, UK) has recently been 
approved as maintenance treatment for COPD in the US 
and EU ( 7 , 8 ). Early dose-ranging studies demonstrated 
improvements in lung function with UMEC over a dose 
range of 62.5 to 1000 μg versus placebo (PBO), with no 
clear dose- diff erentiation ( 9 ). A further dose-ranging 
study of UMEC with doses from 15.6 to 125 μg once 
daily demonstrated dose ordering, with UMEC 125 μg 
showing the greatest benefi t in lung function and res-
cue use, yet similar safety profi les to the lower doses 
( 10 ). To fully characterize the effi  cacy and safety profi le 
of UMEC, two doses of UMEC (62.5 and 125 μg) were 
investigated in subsequent studies. 
 Here, we report the results of two studies that evaluated 
the effi  cacy and safety of once-daily UMEC (62.5 μg and 
125 μg) when added to twice-daily FP/SAL (250/50 μg) 
in patients with COPD. Th e study was designed primar-
ily to assess lung function, although other endpoints were 
assessed. 
 Methods 
 Study designs 
 Th e two studies reported here were 12-week, random-
ized, double-blind, parallel-group studies. Study 1 (Clin-
icalTrials.gov registration number: NCT01772134; GSK 
study number: AC4116135) was conducted in Canada, 
Germany, the Republic of Korea, and the US. Study 2 
(ClinicalTrials.gov registration number: NCT01772147; 
GSK study number: AC4116136) was conducted in 
Chile, the Czech Republic, the Republic of Korea, 
Poland, and the United States. 
 Th e primary objective of both studies was to compare 
the effi  cacy and safety of UMEC (administered at a dose 
of 62.5 μg or 125 μg) plus FP/SAL (UMEC + FP/SAL) 
with PBO + FP/SAL in patients with COPD. 
 Eligible patients were 40 years of age or older and 
had an established history of COPD as defi ned by the 
American Th oracic Society/European Respiratory Soci-
ety ( 11 ). Inclusion criteria were: current or former ciga-
rette smoker with a smoking history of 10 pack-years 
or more; a pre- and post-salbutamol (albuterol) forced 
expiratory volume in 1 second (FEV 1 )-to-forced-vital-
capacity (FVC) ratio < 0.70 and a post-albuterol FEV 1 of 
70% of predicted normal values or less (calculated from 
National Health and Nutrition Examination Survey III 
reference equations ( 12 , 13 ); and a score of 2 or higher on 
the modifi ed Medical Research Council Dyspnea Scale 
( 14 ) at study Visit 1. Exclusion criteria included: hospital 
admission for COPD or pneumonia within the 12 weeks 
before study Visit 1; or a present diagnosis of asthma 
or other known respiratory disorder. Full inclusion and 
exclusion criteria are described in the Supplementary 
materials. 
 Both studies were approved by the relevant local 
 ethics review committees and conducted in accordance 
with the Declaration of Helsinki ( 15 ) and Good Clinical 
Practice guidelines. All patients gave written, informed 
consent before study participation. 
 Randomization and blinding 
 Both studies were multicenter, randomized, double-
blind, parallel-group trials. Patients entered a 4-week 
open-label run-in treatment with FP/SAL 250/50 μg. 
After the run-in period, the eligible patients were ran-
domly assigned in a 1:1:1 ratio to once-daily UMEC 
62.5 μg (delivering 55 μg), UMEC 125 μg (delivering 113 
μg), or PBO administered double-blind via ELLIPTA™
dry powder inhaler, plus FP/SAL (250/50 μg adminis-
tered twice daily, delivering 220/21 μg) administered 
open-label via DISKUS™ inhaler over a 12-week treat-
ment period. Th e randomization schedule was gener-
ated using a validated computerized system (RandAll 
version 2.14) and patients were randomized using an 
Interactive Voice Response System. Concurrent use of 
albuterol was  permitted as rescue medication through-
out the study. 
 Outcomes and assessments 
 For both studies, the primary effi  cacy measure was 
trough FEV 1 at Day 85 (defi ned as the mean of the FEV 1
values obtained 23 and 24 hours after dosing on Day 
84). Th e secondary endpoints were weighted-mean 
(WM) FEV 1 over 0–6 hours post-dose at Day 84 and 
rescue albuterol use (percentage of rescue-free days 
and mean number of puff s per day). Th e proportion of 
patients achieving an increase of ≥ 0.100 L above base-
line in trough FEV 1 was also assessed as a lung function 
 endpoint .
 It has been reported that a change in pre-dose FEV 1
of approximately 0.100 L can be perceived by patients 
( 16 ), and therefore this was considered a clinically-
meaningful improvement. Other lung function end-
points assessed were: trough FEV 1 at Days 2, 28, 56, and 
84 and WM FEV 1 over 0–6 hours post-dose at Day 1; 
proportion of patients achieving an increase in FEV 1
of ≥ 12% and ≥ 0.200 L above baseline at any time during 
0–6 hours post-dose at Day 1; peak FEV 1 on Days 1, 28, 
and 84; serial FEV 1 at 15 and 30 min, 1, 3, 6, 23, and 24 
hours after dosing on Days 1, 28, and 84; and serial and 
trough FVC. 
 Health-related quality of life (HRQoL) outcomes 
included COPD Assessment Test (CAT) and St. 
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George's Respiratory Questionnaire (collected as 
SGRQ for patients with COPD, but converted to and 
reported as SGRQ). Baseline measures for the CAT 
and SGRQ were taken at Visit 2 after 4 weeks of treat-
ment with open-label FP/SAL, consistent with the 
timing of other baseline assessments. A reduction in 
SGRQ score of 4 points was considered the minimally 
clinically important diff erence (MCID) ( 17 ). Safety 
and tolerability assessments included the incidence 
of adverse events (AEs), vital signs (including pulse 
rate and systolic and diastolic blood pressure), and 
the recording of COPD exacerbations. Th e incidence 
of AEs of special interest, including cardiovascular 
events, was assessed using Standardised Medical 
Dictionary for Regulatory Activities Queries: cardiac 
arrhythmias, cardiac failure, ischemic heart disease, 
central nervous system hemorrhages, cerebrovascular 
conditions, pneumonia, and lower respiratory tract 
infections. A COPD exacerbation was defi ned as an 
acute worsening of symptoms of COPD requiring the 
use of any treatment beyond study medication or res-
cue albuterol/salbutamol. 
 Statistical analyses and sample size considerations 
 For both studies, sample size calculations used a two-
sided signifi cance level of 5% and an estimate of the 
residual standard deviation (SD) for trough FEV 1 of 
0.220 L. It was calculated that 160 patients per treat-
ment group would provide 90% power to detect a 
0.080 L diff erence between UMEC + FP/SAL treatment 
groups and PBO + FP/SAL in trough FEV 1 . To account 
for a 20% withdrawal rate, approximately 600 patients 
(200 patients per treatment) were to be randomized in 
each study. 
 Th e primary analysis was performed on the intent-
to-treat (ITT) population, which was defi ned as all 
patients randomized to treatment who received at 
least one dose of study drug. Th e primary endpoint 
was analyzed using a mixed models repeated measures 
(MMRM) analysis ( 18 ) with baseline FEV 1 , smoking 
status, day (as a categorical variable) and treatment as 
covariates. Day-by-baseline interaction and day-by-
treatment interaction were included to estimate treat-
ment eff ect at each day. Th e model used all available 
trough FEV 1 values recorded on Days 2, 28, 56, 84, and 
85. Th e analysis of 0−6 hours’ WM FEV 1 on Day 84 was 
done in a similar way. Estimated diff erences between 
each dose of UMEC + FP/SAL and PBO + FP/SAL were 
presented together with 95% confi dence intervals and 
p-values. Rescue medication use (mean puff s/day over 
Weeks 1–12) was analyzed using an analysis of cova-
riance model adjusting for baseline, treatment group, 
and smoking status. 
 To account for multiplicity across treatment 
 comparisons and key endpoints, a step-down, closed 
testing procedure was used (further details are 
included as Supplementary Materials), as reported 
previously ( 19 ). 
 Results 
 Patients 
 In Study 1, 862 patients were enrolled across 16 cen-
ters in Canada, 33 centers in Germany, 8 centers in the 
Republic of Korea, and 13 centers in the US. In total, 617 
patients were randomized to treatment, 614 received at 
least one dose of study medication and were included in 
the ITT population, and of these 552 (90%) completed 
the study (Figure  1 A). In Study 2, 872 patients were 
enrolled across 8 centers in Chile, 11 centers in the Czech 
Republic, 8 centers in the Republic of Korea, 8 centers in 
Poland, and 17 centers in the United States. In total, 608 
were randomly assigned to treatment, 606 received at 
least one dose of study medication and were included 
in the ITT population, and 532 (88%) completed the 
study (Figure  1 B). Patient demographics and charac-
teristics were well balanced between treatment groups 
and between studies, except the proportion of females 
in Study 2 was lower for UMEC 62.5 μg + FP/SAL com-
pared with the other treatment groups (Table   1 ) and 
there were more current smokers in Study 1 (50−57%) 
than in Study 2 (36−39%). 
 Outcomes 
Lung function
 In both studies, treatment with either dose of UMEC 
(62.5 μg or 125 μg) + FP/SAL resulted in statistically sig-
nifi cant and clinically-meaningful mean improvements 
of 0.127–0.148 L in trough FEV 1 at Day 85 compared 
with PBO + FP/SAL (both  p < 0.001; Table  2 , Figure  2 ). 
Statistically signifi cant improvements exceeding 0.100 L 
compared with PBO + FP/SAL were also demonstrated 
at Days 2, 28, 56, and 84 (either UMEC dose in either 
study; all  p < 0.001; Figure  2 ). 
 For 0–6 hours post-dose WM FEV 1 at Day 84, treat-
ment with either dose of UMEC (62.5 μg or 125 μg) + 
FP/SAL resulted in statistically signifi cant mean 
improvements of 0.144–0.165 L compared with PBO + 
FP/SAL in both studies (all  p < 0.001; Table  2 ; Figure  3 ). 
Statistically signifi cant improvements compared with 
PBO + FP/SAL were also demonstrated at Days 1 and 
28 (either UMEC dose in either study; all  p < 0.001; 
Figure  3 ). 
 Additional lung function endpoint data for both 
studies are presented in Table  2 and Figure  4 . Com-
pared with PBO + FP/SAL, both doses of UMEC + FP/
SAL (62.5 μg or 125 μg) in both studies were associ-
ated with greater odds of having an increase in trough 
FEV 1 of ≥ 0.100 L above baseline at each visit (versus 
not having this increase; all  p < 0.001), greater odds 
of having an increase in FEV 1 of ≥ 12% and ≥ 0.200 L 
above baseline at any time during 0–6 hours post-
dose at Day 1 (versus not having this increase; all 
p < 0.001), greater improvements from baseline in 
peak FEV 1 at each visit (all  p < 0.001), greater improve-
ments from baseline in trough FVC at each visit 
(all  p < 0.001), and consistently greater serial FEV 1
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 measurements (Figure  4 ). Serial FEV 1 profiles on Day 
1 and Day 84 showed sustained benefits for 24 hours 
post-dose. Overall, the magnitude of improvements 
in lung function endpoints compared with PBO + FP/
SAL was similar for both doses of UMEC (62.5 μg or 
125 μg) + FP/SAL. 
 Rescue use 
 In both studies, patients receiving UMEC + FP/SAL 
(62.5  μg or 125 μg) experienced a greater overall pro-
portion of rescue-free days, and a greater increase from 
baseline in the proportion of rescue-free days, compared 
with PBO + FP/SAL (Table  2 ). 
 Figure 1.  Summary of patient disposition in Study 1 (A) and Study 2 (B). 
AE, adverse event; FP/SAL, fl uticasone propionate/salmeterol combination; ITT, intent-to-treat; PBO, placebo; PP, per protocol; UMEC, umeclidinium.
*The run-in population included screening failures, run-in failures, and those in the ITT population (i.e., any patient who took at least one dose of open-label FP/SAL 
during the run-in period). Study 1: Reasons for withdrawal: PBO + FP/SAL: AE ( n = 6), withdrew consent ( n = 3), lost to follow-up ( n = 2), protocol deviation ( n = 4), lack of 
effi cacy ( n = 11), subject reached protocol-stopping criteria ( n = 1); UMEC 62.5 + FP/SAL: PBO + FP/SAL: AE ( n = 5), withdrew consent ( n = 1), protocol deviation ( n = 3), 
lack of effi cacy ( n = 5); UMEC 125 + FP/SAL: AE ( n = 10), withdrew consent ( n = 5), protocol deviation ( n = 3), lack of effi cacy ( n = 3). Study 2: Reasons for withdrawal: 
PBO + FP/SAL: AE ( n  = 13), withdrew consent ( n = 7), lost to follow-up ( n = 1), protocol deviation ( n = 2), lack of effi cacy ( n = 8); UMEC 62.5 + FP/SAL: AE ( n = 10), 
withdrew consent ( n = 8), protocol deviation ( n = 1), lack of effi cacy ( n = 6); UMEC 125 + FP/SAL: AE ( n = 6), withdrew consent ( n = 4), lost to follow-up ( n = 1), protocol 
deviation ( n = 1), lack of effi cacy ( n = 6). 
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line (Table  2 ). In Study 2, the decrease from baseline in 
both UMEC + FP/SAL groups was close to the MCID 
for SGRQ (4 units). Compared with PBO + FP/SAL, in 
Study 1 no statistically signifi cant diff erences in SGRQ 
score were observed with UMEC + FP/SAL (62.5 μg or 
125 μg) at Days 28 or 84 (Table  2 ). However, in Study 
2 statistically signifi cant improvements in SGRQ score 
were observed for UMEC 62.5 μg + FP/SAL (Day 28 
only, not Day 84) and UMEC 125 μg + FP/SAL (Days 28 
and 84) compared with PBO + FP/SAL (Table  2 ). 
 Safety and tolerability 
 In Study 1, the incidence of AEs and serious AEs (SAEs) 
was similar across treatment groups (Table  3 ). In Study 
2, the overall incidence of on-treatment AEs was simi-
lar across the treatment groups, but the incidence of 
SAEs was higher in the PBO + FP/SAL group (both 
UMEC + FP/SAL groups: 3%; PBO + FP/SAL: 7%). In 
 Table 1.  Patient demographics and characteristics (ITT population) at screening and baseline 
Study 1 Study 2
PBO + 
FP/SAL 250/50
UMEC 62.5 + 
FP/SAL 250/50




UMEC 62.5 + 
FP/SAL 250/50
UMEC 125 + 
FP/SAL 250/50
( n = 205) ( n = 204) ( n = 205) ( n = 201) ( n = 203) ( n = 202)
Age, years 63.4 (8.27) 62.7 (7.84) 63.2 (8.95) 65.7 (7.92) 64.5 (8.31) 65.5 (7.89)
Male,  n (%) 132 (64) 133 (65) 142 (69) 123 (61) 140 (69) 120 (59)
Current smoker at screening a ,  n (%) 116 (57) 102 (50) 115 (56) 77 (38) 73 (36) 78 (39)
Smoking pack-years 48.4 (25.86) 49.8 (24.53) 50.4 (27.88) 45.1 (25.73) 44.3 (27.76) 42.8 (21.76)
Post-albuterol % predicted FEV 1 47.4 (13.34) 46.8 (12.35) 46.7 (13.12) 44.8 (13.32) 43.9 (11.53) 47.6 (12.77)
Post-albuterol FEV 1 /FVC 47.39 (10.818) 46.72 (9.758) 46.63 (10.972) 44.58 (11.117) 45.02 (10.622) 47.06 (11.076)
Baseline FEV 1, L 1.310 (0.4602) 1.312 (0.4745) 1.354 (0.5405) 1.137 (0.4507) 
b 1.155 (0.4419) 1.207 (0.4789)
Baseline FVC, L 2.758 (0.8382) 2.785 (0.8120) 2.854 (0.9147) 2.508 (0.7880) b 2.599 (0.7970) 2.592 (0.8482)
Percent reversibility to albuterol 14.5 (13.48) 16.2 (14.37) 16.2 (14.25) 13.4 (12.54) 16.1 (13.22) c 16.6 (14.43)
Rescue-free days at baseline, % d 45.4 (41.61) 46.8 (41.45) 44.4 (41.88) 39.1 (42.20) 40.9 (41.37) 37.8 (40.63)
Number of puffs of rescue medication (albuterol)/day d 1.9 (2.40) 1.9 (2.27) 2.1 (2.64) 2.2 (2.37) 2.4 (2.90) 2.2 (2.41)
CAT score at baseline 18.16 (7.021) 17.79 (7.404) 18.71 (6.921) 18.08 (7.425) 18.12 (7.347) 17.02 (7.075)
SGRQ score at baseline e 43.97 (17.558) 43.38 (17.572) 45.39 (16.145) 47.80 (17.678) 46.40 (16.713) 44.94 (15.689)
GOLD stage, n (%)
 II 100 (49) 89 (44) 91 (44) 78 (39) 71 (35) 95 (47)
 III 84 (41) 100 (49) 85 (41) 92 (46) 108 (53) 88 (44)
 IV 21 (10) 15 (7) 29 (14) 31 (15) 24 (12) 19 (9)
Reversible f to albuterol,  n (%) 69 (34) 80 (39) 77 (38) 55 (27) 62 (31) c 66 (33)
Reversible f to albuterol and ipratropium g , n (%) 106 (52) 118 (58) 121 (59) 104 (53) 103 (52) 115 (58)
Any pre-treatment concomitant medication, n (%) 196 (96) 187 (92) 186 (91) 189 (94) 196 (97) 195 (97)
 Long-acting β 2 -agonist, n (%) 114 (56) 118 (58) 113 (55) 128 (64) 132 (65) 132 (65)
 Inhaled corticosteroids, n (%) 98 (48) 112 (55) 106 (52) 121 (60) 119 (59) 122 (60)
 Long-acting muscarinic antagonist, n (%) 92 (45) 82 (40) 94 (46) 60 (30) 65 (32) 57 (28)
 CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; FEV 1 , forced expiratory volume in 1 second; FP/SAL, fl uticasone propionate/salmeterol combination; FVC, forced vital 
capacity; GOLD, Global initiative for Obstructive Lung Disease; ITT, intent-to-treat; PBO, placebo; SD, standard deviation; SGRQ, St. George's Respiratory Questionnaire; UMEC, umeclidinium. 
 Values are reported as mean (SD) unless otherwise stated. 
aReclassifi ed: Patient reclassifi ed as current smoker if smoked within 6 months;  b n = 200;  c n = 202;  d Study 1: PBO + FP/SAL 250/50,  n = 203; UMEC 62.5 + FP/SAL 250/50,  n = 202; UMEC 
125 + FP/SAL 250/50,  n = 200; Study 2: PBO + FP/SAL 250/50,  n = 196, UMEC 62.5 + FP/SAL 250/50,  n = 202; UMEC 125 + FP/SAL 250/50,  n = 195;  e Study 1: PBO + FP/SAL 250/50,  n 
= 203; UMEC 62.5 + FP/SAL 250/50,  n = 200; UMEC 125 + FP/SAL 250/50,  n = 204; Study 2: PBO + FP/SAL 250/50,  n = 201, UMEC 62.5 + FP/SAL 250/50,  n = 202; UMEC 125 + FP/SAL 
250/50,  n = 198;  f reversible to albuterol (and to albuterol and ipratropium) was defi ned as an increase in FEV 1 of ≥ 12% and ≥ 200 mL following administration of the drug(s);  
g in Study 1, 
 n = 203 for PBO + FP/SAL 250/50,  n = 204 for UMEC 62.5 + FP/SAL 250/50,  n = 204 for UMEC 125 + FP/SAL 250/50; in Study 2,  n = 198 for PBO + FP/SAL 250/50,  n = 199 for UMEC 62.5 + 
FP/SAL 250/50,  n = 200 for UMEC 125 + FP/SAL 250/50. 
 Statistically signifi cant reductions in rescue use were 
observed for both UMEC + FP/SAL groups compared 
with PBO + FP/SAL in Study 1 (0.3 puff s/day, both  p <
0.05; Table  2 ), but only for UMEC 125 μg + FP/SAL in 
Study 2 (0.5 puff s/day; Table  2 ). 
 HRQoL 
 In both studies, numerical decreases in CAT scores 
(denoting an improvement) were observed in all treat-
ment groups at Day 28 and Day 84 compared with 
baseline, except for the PBO + FP/SAL group at Day 
84 in Study 2 (Table  2 ). Decreases in CAT score were > 
0.50 greater for all UMEC + FP/SAL groups compared 
with PBO + FP/SAL on both days, with the exception of 
Study 1 at Day 84 (Table  2 ). 
 Similarly, decreases in SGRQ total score (denoting 
improvement in HRQoL) were observed for all treat-
ment groups at Day 28 and Day 84 compared with base-
6 Siler et al.
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both studies, headache and nasopharyngitis were the 
most commonly reported AEs across all treatment 
groups (3–7% and 2–5%, respectively; Table  3 ). Addi-
tional details on drug-related AEs and AEs of special 
interest are presented in the Supplementary Materials 
and Supplementary  Table 1. 
 In Study 1, one death possibly related to study drug 
in the UMEC 125 μg + FP/SAL group was reported 
in a patient with extensive cardiovascular disease 
(additional details provided in Supplementary Mate-
rials). In Study 2, two deaths were reported during the 
treatment phase; one in the PBO + FP/SAL group and 
one in the UMEC 62.5 μg + FP/SAL group (additional 
details provided in Supplementary Materials). Nei-
ther of the deaths were considered to be related to the 
study drug. 
 No clinically relevant treatment-related changes in 
vital signs were reported in either study. In both studies, 
fewer on-treatment COPD exacerbations were reported 
with either dose of UMEC + FP/SAL compared with 
PBO + FP/SAL (Table  3 ). 
 Discussion 
 Th e fi ndings from these two randomized, double-blind, 
parallel-group studies show that the addition of once-
daily UMEC (62.5 or 125 μg) to twice-daily FP/SAL 
(250/50 μg) resulted in statistically signifi cant and clin-
ically-meaningful improvements in measures of lung 
function when compared with PBO + FP/SAL over 12 
weeks in patients with COPD. A statistically signifi cant 
reduction in rescue medication use, an objective mea-
sure of improvement noticeable by patients, was also 
observed with UMEC 125 μg + FP/SAL compared with 
PBO + FP/SAL in both studies, and with UMEC 62.5 
μg + FP/SAL in Study 1. Th ese fi ndings are consistent 
with the results of other clinical studies of UMEC 62.5 
and 125 μg, which reported improvements in trough 
FEV 1 , dyspnea (as measured by transitional dsypnea 
index), HRQoL (as measured by the SGRQ) and rescue 
medication use (i.e., a reduction) compared with PBO 
( 10 , 20 , 21 ). Th is indicates that the benefi t of UMEC 
monotherapy over PBO is maintained when adminis-
tered on a background of ICS/LABA therapy. 
 Th e combined use of ICS and/or LABA or LAMA 
therapy is recommended as a fi rst-line therapy for 
patients with symptomatic COPD and a high risk of 
exacerbations ( 2 ). Th e addition of a LAMA to ICS/LABA 
therapy may also provide increased effi  cacy compared 
with ICS/LABA therapy alone. Th is is supported by 
clinical study data showing that the addition of tiotro-
pium (LAMA) to ICS/LABA therapy (budesonide/for-
moterol or FP/SAL) resulted in improvements in lung 
function, COPD symptoms, health status and severe 
exacerbations (i.e., a reduction) versus tiotropium 
alone ( 4 , 5 , 22 – 24 ). Th ese studies also showed that the 
number and type of AEs reported with triple therapy 
were generally similar to those reported with dual or 
 Figure 3.  LS mean (95% CI) change from baseline in 0–6 hours WM FEV 1 (L) in 
Study 1 (A) and Study 2 (B) (ITT). 
 CI, confi dence interval; FEV 1 , forced expiratory volume in 1 second; FP/SAL, 
fl uticasone propionate/salmeterol combination; ITT, intent-to-treat; LS, least 
squares; PBO, placebo; UMEC, umeclidinium; WM, weighted mean. Analysis 
performed using a repeated measures model with covariates of treatment, baseline 
(mean of the two assessments made 30 minutes and 5 minutes pre-dose on Day 
1), smoking status, Day, Day by baseline and Day by treatment interactions. 
 Figure 2.  LS mean (95% CI) change from baseline in trough FEV 1 (L) in Study 1 
(A) and Study 2 (B) (ITT). 
CI, confi dence interval; FEV 1 , forced expiratory volume in 1 second; FP/SAL, 
fl uticasone propionate/salmeterol combination; ITT, intent-to-treat; LS, least 
squares; PBO, placebo; UMEC, umeclidinium. Analysis performed using a 
repeated measures model with covariates of treatment, baseline (mean of the two 
assessments made 30 minutes and 5 minutes pre-dose on Day 1), smoking status, 
Day, Day by baseline and Day by treatment interactions. 
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 Figure 4.  Serial (24 hours) FEV 1 LS mean (95% CI) change from baseline on Day 1 and Day 84 (ITT population) in Study 1 (A) and Study 2 (B). 
CI, confi dence interval; FEV 1 , forced expiratory volume in 1 second; FP/SAL, fl uticasone propionate/salmeterol combination; ITT, intent-to-treat; LS, least squares; PBO, 
placebo; UMEC, umeclidinium. Analyses performed using a separate repeated measures model for each Day with covariates of treatment, baseline (mean of the two 
assessments made 30 minutes and 5 minutes pre-dose on Day 1), smoking status, time, time by baseline and time by treatment interactions. 
monotherapy agents for periods of up to one year, and 
were mostly related to their pharmacological mode of 
action. 
 A recent retrospective study conducted in a UK-
based COPD cohort (National Health Service Tayside 
Respiratory Disease Information System) also assessed 
the impact of adding tiotropium to ICS/LABA therapy 
( 25 ). Th is study revealed that triple therapy may reduce 
all-cause mortality, hospital admissions and oral cortico-
steroid bursts compared with ICS/LABA therapy alone. 
Overall, the results of this study support the rationale for 
LAMA/ICS/LABA triple therapy in COPD and extend 
the results of similar studies ( 3 , 4 , 26 ), with UMEC + 
FP/SAL providing more eff ective bronchodilation at the 
beginning and end of the dosing interval compared with 
PBO + FP/SAL. 
 All three treatments (PBO + FP/SAL, UMEC 125 μg + 
FP/SAL, and UMEC 62.5 μg + FP/SAL) demonstrated 
improvements from baseline in CAT scores. Recently, 
an MCID of 2 points was identifi ed by Kon et al. ( 27 ). 
Although the diff erences from baseline reported in this 
study did not reach that magnitude (improvements of 
0.81–1.42 for active treatments), it should be consid-
ered that the MCID was identifi ed for a change from 
(untreated) baseline, whereas in these studies the base-
line measurement was taken after a 4-week period on 
active treatment for COPD (FP/SAL). Th ese additional 
improvements over FP/SAL therapy therefore represent 
a potentially clinically meaningful diff erence to PBO 
alone. Improvements from baseline were also noted in 
SGRQ scores with the three treatment groups. 
 However, no consistent statistically signifi cant diff er-
ences in SGRQ total score were observed between the 
treatment groups, with the exception of UMEC 125 μg + 
FP/SAL compared with PBO + FP/SAL in Study 2. It is 
unclear why diff erences were not observed between the 
UMEC + FP/SAL and PBO + FP/SAL treatment groups 
across these two studies, as improvements in rescue 
use were observed. One potential reason may be that 
baseline SGRQ and CAT scores were measured after 
4 weeks of treatment with FP/SAL. In addition, the two 
studies were designed to evaluate lung function effi  cacy 
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 measures, and larger studies may be required to deter-
mine a benefi t on patient-reported outcomes. 
 Both doses of UMEC + FP/SAL were well tolerated, 
with the overall incidence of on-treatment AEs similar 
to PBO + FP/SAL in both studies. In the two studies 
reported here, the combination of UMEC (a LAMA) 
with FP/SAL (an ICS/LABA) did not result in increased 
cardiovascular AEs. Overall, both doses of UMEC + 
FP/SAL demonstrated similar effi  cacy and safety in the 
overall study population, and no substantial clinical 
benefi t was observed with the UMEC 125-μg dose over 
the UMEC 62.5-μg dose when added to FP/SAL. 
 Although these studies demonstrate that the addi-
tion of UMEC to FP/SAL results in clinically signifi cant 
improvements in lung function, they were not designed 
to assess the eff ect of the addition of UMEC to FP/SAL 
on exacerbations, which may require studies of longer 
duration and larger sample size. Th ese studies would 
also provide longer-term safety data on the triple regi-
men. As such, the role of triple LAMA/LABA/ICS ther-
apy compared with dual LAMA/LABA therapy in the 
COPD treatment paradigm is still under investigation. 
 Conclusions 
 Th e fi ndings from both studies demonstrate that the 
addition of UMEC 62.5 μg or  UMEC 125 μg to FP/SAL 
resulted in statistically signifi cant improvements in 
measures of lung function compared with PBO + FP/
SAL over 12 weeks. Both doses of UMEC + FP/SAL 
were well tolerated, with no notable treatment-related 
diff erences in AEs or changes in vital signs, and no 
additional safety concerns identifi ed with the addition 
of UMEC to FP/SAL over a 12-week treatment period. 
Overall, these data suggest that patients with COPD 
can obtain additional benefi ts from the addition of 
UMEC to FP/SAL. 
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 Table 3.  Summary of on-treatment AEs reported by ≥ 3% of patients in any treatment group 
Study 1 Study 2
PBO + 
FP/SAL 250/50
UMEC 62.5 + 
FP/SAL 250/50




UMEC 62.5 + 
FP/SAL 250/50
UMEC 125 + 
FP/SAL 250/50
( n = 205) ( n = 204) ( n = 205) ( n = 201) ( n = 203) ( n = 202)
Any on-treatment AEs, n (%) 85 (41) 78 (38) 76 (37) 74 (37) 78 (38) 73 (36)
Most common on-treatment AEs, n (%) a 
 Headache 10 (5) 9 (4) 14 (7) 9 (4) 9 (4) 6 (3)
 Nasopharyngitis 10 (5) 5 (2) 5 (2) 9 (4) 6 (3) 10 (5)
 Cough 3 (1) 7 (3) 5 (2) 1 (< 1) 3 (1) 1 (< 1)
 Upper respiratory tract infection 6 (3) 1 (< 1) 3 (1) 4 (2) 6 (3) 5 (2)
 Back pain 5 (2) 2 (< 1) 4 (2) 5 (2) 5 (2) 6 (3)
 Pneumonia 0 1 (< 1) 2 (< 1) 6 (3) 3 (1) 5 (2)
 COPD 3 (1) 2 (< 1) 1 (< 1) 8 (4) 3 (1) 1 (< 1)
Any on-treatment SAEs, n (%) 8 (4) 4 (2) 6 (3) 15 (7) 6 (3) 6 (3)
 Any AEs leading to permanent discontinuation of 
medication/withdrawal, n (%)
6 (3) 4 (2) 10 (5) 12 (6) 9 (4) 6 (3)
 Fatal AEs, n (%) 0 0 1 (< 1) 1 (< 1) 1 (< 1) 0
Number of patients with a COPD exacerbation, n (%) b 13 (6) 9 (4) 7 (3) 20 (10) 10 (5) 8 (4)
Number of COPD exacerbations
 0 192 (94) 195 (96) 198 (97) 181 (90) 193 (95) 194 (96)
 1 13 (6) 9 (4) 7 (3) 20 (10) 10 (5) 8 (4)
≥ 2 0 0 0 0 0 0
 AE, adverse event; COPD, chronic obstructive pulmonary disease; FP/SAL, fl uticasone propionate/salmeterol combination; PBO, placebo; SAE, serious adverse event; UMEC, umeclidinium. 
aReported by ≥ 3% of patients on any treatment in either study;  b percentages calculated using n as the denominator. 
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